NCT02279394: E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in Hi R SMM
NCT02315716: Phase 2 -Carfilzomib/Cyclophosphamide/Dex With Maint. Carfilzomib - NDMM Cardamon Study
NCT02203643: Phase 2 - Carf/Cyclo./Dex Vs Carf/Len/Dex -> ASCT or 12 Cy Carf/Len/Dex - NDMM - FORTE
NCT01985126: Phase 2 - Dara in MM who had 3 prior lines inc. PI, Imid - or db. ref. MMY2002 (SIRIUS)
NCT01816971: Phase 2 - Carfilzomib, Lenalidomide, and Dexamethasone Before and After ASCT NDMM
NCT01782963: Phase 2 - Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM) (RVD Lite)
NCT01946477: Phase 2 -Pomalidomide Combination With Low-dose Dex +/- Dara in RRMM Myeloma POM MM 014
NCT01775553: Phase 2- High Dose Carfilzomib in Myeloma Patients Who Have Progressed On Standard Dose
NCT01572480: Phase 2: Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
NCT01729091: Phase 2: Umbilical Cord Blood-Derived NK Cells, Elotuzumab, Len, Melphalan f/b ASCT
NCT01402284: Phase 2 - Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients
NCT01346787: EMN - Phase 2: Carfilzomib, Cyclophosphamide and Dexamethasone Newly Diagnosed Myeloma
NCT01415882: Phase 2: Ixazomib Citrate in Relapsed Multiple Myeloma, Not Refractory to Bortezomib
NCT01190787: Phase 2: EMN - Velcade/Melphalan/Pred or Velcade/Cycloposphamide/Pred or Velcade/Pred.
Phase 2: Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed MM
NCT00833560: Phase 2: A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients NDMM
NCT00609167: Phase 2: Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With NDMM
NCT00511238: Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma
NCT00572169: UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy.